A Phase 4 interventional study of TAP (transversus abdominis plane block) and QL (quadratus lumborum block) in Cesarean Section and Postoperative Pain, sponsored by Medical University of Lublin. Completed at 1 site in Poland. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Medical University of Lublin · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Pain, Postoperative with a site in Poland — 8 open to participants now, 9 under way, none of them phase 3. Pain, Postoperative · Poland.
Among the 48 studies in Pain, Postoperative with a site in Poland, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 7 that started in 2018, is one of 16 in phase 4, and was the 20th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →8 of the 48 studies in Pain, Postoperative with a site in Poland are open now. Recruiting first, the newest first:
Centre of Postgraduate Medical Education · Sites in Poland
Ages 18+ · Men only
Centre of Postgraduate Medical Education · Sites in Poland
Ages 18–75 · Women only
Medical University of Silesia · Sites in Poland
Ages 18–75
University of Warmia and Mazury in Olsztyn · Sites in Poland
Ages 18–80
Medical University of Lodz · Sites in Poland
Ages 25–70
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 104 across the 45 interventional studies, 200 across the 3 observational. Of the 35 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 48 have an industry lead sponsor. The 10 most frequent:
Medical University of Lublin is the lead sponsor of 62 studies on the registry; 11 are open to participants now.
Medical University of Lublin has 7 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
2 of the studies in Pain, Postoperative with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264699University of Warmia and Mazury in OlsztynVisually Guided TAP Block in Laparoscopic TAPP Hernia Repair | 2026-12 |
| NCT07434427Medical University of SilesiaComparison of the Efficacy and Safety of Intravenous Buprenorphine Administered Via PCA System Versus Oxycodone in the Management of Postoperative Pain After Video-Assisted Thoracoscopic Surgery | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Pain, Postoperative with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Comparison of two types of analgesia after cesarean section All patients will be anesthetized with spinal technique. Ultrasound-guided transversus abdominis plane or quadratus lumborum block to treat postoperative pain. Postoperative pain will be measured with visual-analog scale (VAS). 1, 2, 6 months after surgery each patient will be called to assess neuropathic pain with Neuropathic Pain Symptom Inventory (NPSI).
Written consent will be obtained before the cesarean section. Only subarachnoidally anesthetized patients may participate in the study. Pencil-point spinal needle and bupivacaine (Marcaine Heavy Spinal 0.5 %) will be used.
At the end of surgery ultrasound-guided regional block will be performed. Each patient will be randomly allocated to one of the treated group: transversus abdominis plane block (TAP) or quadratus lumborum (QL). Patients receive 0.2 mL of local anesthetic solution (0.375 % ropivacaine) on each side.
Postoperative pain will be measured with VAS (visual-analog scale) 2, 4, 8, 12 and 24 hours after the end of the operation.
Paracetamol, metamizole, ketoprofen may be given as required. Whenever pain exceeds 40 (VAS) 5 mg of morphine will be given intravenously (maximum two dosages per day).
1, 3, 6 months patients will be called to assess neuropathic pain. Neuropathic Pain Symptom Inventory (NPSI) will be used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ultrasound-guided transversus abdominis plane block at the end of cesarean section
Procedure: TAP (transversus abdominis plane block) · Drug: Ropivacaine · Device: Needle · Drug: paracetamol · Drug: metamizole · Drug: Ketoprofen · Drug: Morphine
Ultrasound-guided quadratus lumborum block at the end of cesarean section
Procedure: QL (quadratus lumborum block) · Drug: Ropivacaine · Device: Needle · Drug: paracetamol · Drug: metamizole · Drug: Ketoprofen · Drug: Morphine
the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Postoperative pain
Acute pain measured with VAS (visual-analogue scale). VAS in milimmeters. Minimum value 0, maximum 100. Less better - less severe pain. 0 no pain at all.
Time frame: up to 24 hours after the surgery
Neuropathic pain
Neuropathic pain occurrence assessed with Neuropathic Pain Symptom Inventory (NPSI) 10 descriptive variables, each one from 0 to 10. 0 means no pain. 10 very high chance of occurrence of neuropathic pain.
Time frame: 6 months from the surgery
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Jan 2019, 11 months.
Of 532 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 11 months is below that.
Counting every sponsor, half of 542 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Lublin